GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Price-to-Free-Cash-Flow

Verici Dx (Verici Dx) Price-to-Free-Cash-Flow : N/A (As of May. 11, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Price-to-Free-Cash-Flow?

As of today (2024-05-11), Verici Dx's share price is $0.12. Verici Dx's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.06. Hence, Verici Dx's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Verici Dx's Price-to-Free-Cash-Flow or its related term are showing as below:

VRCDF's Price-to-Free-Cash-Flow is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 26.82
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Verici Dx's Free Cash Flow per Share for the six months ended in Jun. 2023 was $-0.03. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.06.


Verici Dx Price-to-Free-Cash-Flow Historical Data

The historical data trend for Verici Dx's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Price-to-Free-Cash-Flow Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22
Price-to-Free-Cash-Flow
- - -

Verici Dx Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23
Price-to-Free-Cash-Flow - - - - -

Competitive Comparison of Verici Dx's Price-to-Free-Cash-Flow

For the Diagnostics & Research subindustry, Verici Dx's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verici Dx's Price-to-Free-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Verici Dx's Price-to-Free-Cash-Flow falls into.



Verici Dx Price-to-Free-Cash-Flow Calculation

Verici Dx's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.12/-0.062
=N/A

Verici Dx's Share Price of today is $0.12.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Verici Dx's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.06.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Verici Dx  (OTCPK:VRCDF) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Verici Dx Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Verici Dx's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Verici Dx (Verici Dx) Business Description

Traded in Other Exchanges
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines